The market for drugs that encourage the immune system to attack tumors could explode in the next three years, leading Bristol ...

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

Bristol Myers Squibb (BMS) is joining forces with BioNTech in a deal that could surpass $11bn as the two drugmakers look to ...

Bristol-Myers Squibb is doubling down on its oncology ambitions with a deal that could reach $11.1 billion, partnering with ...

By Michael Erman and Ludwig Burger (Reuters) -Bristol Myers Squibb has agreed to pay up to $11.1 billion in a partnership ...

Bristol-Myers makes an $11 billion deal with BioNTech to join the new cancer-treatment game, nearly double the size of Pfizer ...

By Michael Erman and Ludwig Burger (Reuters) -Bristol Myers Squibb will pay $1.5 billion upfront to partner with Germany's ...

Data presented at ASCO show that swapping in the oral drug camizestrant for an older therapy helped sustain the benefit of ...

This is the web version of STAT’s special newsletter from the annual meeting of the American Society of Oncology. For more ...

The BREAKWATER study enrolled patients with newly diagnosed colon cancer that harbors a mutation called BRAF 600E that makes ...

Western drugmakers, investors increasingly aim to acquire Chinese compounds.

Pfizer is paying $1.25 billion to join the PD-(L1)xVEGF bispecific race. | Pfizer is paying $1.25 billion to join the ...